Expression of FLIPLong and FLIPShort in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis

被引:0
作者
M Benesch
U Platzbecker
J Ward
H J Deeg
W Leisenring
机构
[1] Fred Hutchinson Cancer Research Center,
[2] University of Washington,undefined
来源
Leukemia | 2003年 / 17卷
关键词
myelodysplasia; FLIP; FLIP; apoptosis;
D O I
暂无
中图分类号
学科分类号
摘要
Several apoptosis-inducing systems, including Fas/Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) and its receptors, are upregulated in myelodysplastic syndrome (MDS). FLIP (FLICE (FAS-associated death-domain-like IL-1β-converting enzyme)-inhibitory protein)) was identified as an inhibitor of FAS and TRAIL signals. Here, we characterized FLIPLong (FLIPL) and FLIPShort (FLIPS) expression in bone marrow mononuclear cells (BMMNCs) and in CD34+ cells of 29 MDS patients, and in 17 normal volunteers. The expression was correlated with apoptotic indices. In CD34+ cells, FLIPL levels were higher among normal individuals than in MDS patients (P=0.04). Among total BMMNC, FLIPL levels also tended to be higher in normal subjects than in MDS patients, although this difference was not significant (P=0.71). FLIPL levels in CD34+ cells were negatively correlated with apoptosis in both normal and MDS marrows (P=0.03). FLIPShort RNA expression was higher in MDS patients than in normal controls in both BMMNC (P=0.03) and CD34+ cells (P=0.08). In contrast to FLIPL, FLIPSt levels were positively correlated with apoptosis. At the protein level FLIP was most readily detectable in patients with high blast counts. The data suggest that FLIPL and FLIPS are differentially regulated, and that the relative levels of both isoforms play a role in the regulation of apoptosis in MDS.
引用
收藏
页码:2460 / 2466
页数:6
相关论文
共 165 条
[1]  
Nagata S(1997)Apoptosis by death factor Cell 88 355-365
[2]  
Parker JE(2000)Excessive apoptosis in low risk myelodysplastic syndromes (MDS) [Review] Leukemia Lymphoma 40 1-24
[3]  
Mufti GJ(1995)Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes Blood 86 268-276
[4]  
Raza A(1997)Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes Leukemia 11 839-845
[5]  
Gezer S(2000)Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates Blood 96 1388-1392
[6]  
Mundle S(2000)The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS Blood 96 3932-3938
[7]  
Gao XZ(2002)Targeting death and decoy receptors of the tumour-necrosis factor superfamily [Review] Nat Rev Cancer 2 420-430
[8]  
Alvi S(1998)Fas/Fas ligand and hematopoietic progenitor cells [Review] Curr Opin Hematol 5 163-165
[9]  
Borok R(1998)TRAIL: a molecule with multiple receptors and control mechanisms [Review] Curr Opin Immunol 10 559-563
[10]  
Bouscary D(1998)Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia Leukemia 12 486-492